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SUPPLEMENTARY MATERIALS
5-bromo-4-methyl-1H-benzotriazole (BrMeBt). To a cooled (2oC) solution of 2-bromo-6-nitrotoluene (1; 3.00 g; 13.88 mmol) in 98% sulfuric acid (30 mL), was added urea nitrate (2; 2.55 g; 20.72 mmol; prepared according to Vogel [32]) in small portions [31]. After 10 minutes stirring at temperature 2-5oC, the reaction mixture was allowed to warm up to room temperature. The reaction was monitored by TLC with hexane:butan-2-ol (100:1), and, after completion, the reaction mixture was poured onto ice. The resulting precipitate was collected by filtration, washed with water, and crystallized from 95% ethanol to give pale yellow crystals of 2-bromo-5,6-dinitrotoluene (3; 3.12 g; 86%).
For reduction of compound 3 a modification of a published procedure was applied [33]. A solution of SnCl2 (8.60 g; 45.36 mmol) in HCl (32.8 mL) was added dropwise to a suspension of 3 (2.00 g; 7.66 mmol) in HCl (7.8 mL). The reaction mixture was stirred at room temperature and reaction progress monitored with TLC (chloroform : methanol, 11:1). The white precipitate of 2-bromo-5,6-diaminotoluene dihydrochloride (4) was collected by filtration and washed with 2 M HCl and diethyl ether to give 1.23 g of 4 (59% crude product). Crude 4 (1.23 g; 4.52 mmol) was suspended in HCl (1.3 mL) and a solution of sodium nitrite (0.43 g; 6.23 mmol) in water (4.35 mL) was added dropwise [34]. The mixture was stirred at room temperature for 3 h, the product collected by filtration, and washed with water and methanol. Crystallization from methanol afforded 5-bromo-4-methyl-1H-benzotriazole (BrMeBt) (0.75 g; 78%). Mp 228.7 – 229.2°C; TLC (silica gel) Rf 0.60 (dichloromethane : methanol 11:1); HRMS m/z calcd for [C7H5BrN3-] 209.9667, found 209.9688; UV MeOH λmax (ε): 262 nm (5170), 266 nm (5330), 280 nm (4620); pH 2: 263.5 nm (5550), 267.5 nm (5710), 279.5 nm (4940); pH 7: 270.5 nm (5760), 279.5 nm (5790); pH 12: 280 nm (6680); 1H NMR 500 MHz (DMSO-d6) δ [ppm] 2.67 (bs, 3H, CH3); 7.57; 7.71 (H-6 and H-7) 13C 500 MHz (DMSO-d6 with water) δ [ppm] 16.71 (CH3); 110.20 (C6); 117.43 (C3); 120.92 (C4); 129.52 (C5); 143.34 (C1); 144.74 (C2). 
4,5,6-tribromo-7-methyl-1H-benzotriazole (Br3MeBt). For bromintion of BrMeBt, a modified procedure described by Zień et al. [30] was applied: BrMeBt (0.75 g; 3.54 mmol) was suspended in 70% nitric acid (11.2 mL), warmed to 80˚C, and bromine (0.9 mL; 5.63 mmol) was added dropwise. The reaction mixture was refluxed and stirred for 48 h and, after completion the mixture, poured onto ice. Crude product was filtered off and crystallized from methanol, giving Br3MeBt (0.55 g; 42%). Mp 271.1 – 271.8 °C; TLC (silica gel) Rf 0.64 (dichloromethane : methanol 11:1); HRMS m/z calcd for [C7H5Br3N3+] 369,8013, found 369,8002; UV λmax (ε) (MeOH : 0.74% CH2Cl2): 282.5 nm (6640); pH 2 (0.74% CH2Cl2): 283 nm (4290); pH 7 (0.74% CH2Cl2): 287 nm (7870); pH 12 (0.74% CH2Cl2): 287.5 nm (7880); 1H NMR 500 MHz (DMSO-d6) δ [ppm] 2.65 (s, 3H, CH3); 13C 500 MHz (DMSO-d6) δ [ppm] 19.64 (CH3); 103.77 (C4); 111.99 (C5); 123.26 (C6); 130.50 (C4a); 133.29 (C7a); 140.01 (C7). 
5-bromo-4-methyl-1H-benzimidazole (BrMeBz). A suspension of 4 (5 g; 18.2 mmol) in 4 M HCl (28 mL) and concentrated formic acid (2.1 mL) was refluxed for 18h [35]. The resulting solid was collected by filtration, and washed with water and methanol. Crystallization from a mixture of methanol and acetone, with addition of activated carbon, gave BrMeBz (3.50 g, 91%). Mp 205.0 – 206.5°C – with decomposition; TLC (silica gel) Rf 0.29 (dichloromethane : methanol 11:1); HRMS m/z calcd for [C8H8BrN2+] 210.9871, found 210.9857; UV λmax (ε) MeOH: 251 nm (4810), 257.5 nm (4510), 278 nm (3960), 286 nm (3750); pH 2: 250.5 nm (3880), 276.5 nm (4540), 284.5 nm (4120); pH 7: 251 nm (5040), 256.5 nm (4800), 277.5 nm (3450), 285.5 nm (3310); pH 12: 254 nm (3810), 258.5 nm (3970), 279.5 nm (4230), 285 nm (4140); 1H NMR 300 MHz (DMSO-d6) δ [ppm] 2.56 (s, 3H, CH3); 7.35 (s, 2H, H-6, H-7); 8.22 (s, 1H, H-2). 
4,5,6-tribromo-7-methyl-1H-benzimidazole (Br3MeBz). Bromination of BrMeBz (3.00 g; 14.21 mmol) was carried out as described for Br3MeBt, and finally crystallized from methanol (2.46 g; 47%) Mp 180°C – with decomposition; TLC (silica gel) Rf 0.47 (dichloromethane : methanol 11:1); HRMS m/z calcd for [C8H6Br3N2+] 368,8061, found 368,8049; UV λmax (ε) MeOH: 260 nm (6630), 285 nm (3070), 296 nm (2750); pH 2: 261 nm (9270), 285 nm (6600), 295 nm (5720); pH 7: 260 nm (11450), 283.5 nm (5590), 295 nm (4830); pH 12: 277 nm (10610), 296 nm (6910); 1H NMR 300 MHz (DMSO-d6) δ [ppm] 2.65 (s, 3H, CH3); 8.92 (s, 1H, H-2).

1. Synthetic Procedures









Scheme 1. Synthesis of TBBt and TBBz; a) Br2, HNO3, reflux





Scheme 2. Synthesis of BrMeBt and Br3MeBt a) H2SO4, 2-5°C; b) SnCl2, HCl; c) NaNO2, H2O, HCl; d) Br2, HNO3, reflux 

The corresponding benzimidazole derivatives were prepared as follows: 5-bromo-4-methyl-1H-benzimidazole (BrMeBz, Scheme 3) was synthesized from 4 according to the procedure of Phillips [35]. Bromination of BrMeBz with the procedure described for Br3MeBt, followed by crystallization from methanol, led to 4,5,6-tribromo-7-methyl-1H-benzimidazole (Br3MeBz) in 47% yield.









Figure S2.  hCK2α activity in the presence of different concentrations of inhibitors


